Baseline demographic and disease characteristics
| Variable | US 3014,7 | MN 3015,7 | MN 3025,6 | ATTRACT9 | ERA 10,13 | European IL1Ra11,12 |
|---|---|---|---|---|---|---|
| RF, rheumatoid factor; DMARDs, disease modifying antirheumatic drugs; CRP, C reactive protein; HAQ-DI, Health Assessment Questionnaire disease index; NR, not reported. | ||||||
| *% Of patients with ≤3 years’ disease duration; †calculated from mean of baseline total Sharp scores divided by mean disease duration for each treatment group; ‡may be overestimated owing to mean disease duration of ≤1 year. | ||||||
| Total No of patients | 482 | 356 | 985 | 428 | 632 | 472 |
| No in each treatment group | 118–182 | 91–134 | 487–495 | 81–88 | 207–217 | 116–121 |
| Mean age (years) | 53–55 | 55–59 | 58 | 51–54 | 49–51 | 52–54 |
| Mean disease duration (years) | 6.5–7.0 | 5.7–7.6 | 3.7–3.8 | 9.2–11.6 | ≤1.0 | 3.7–4.3 |
| ≤2 Years’ disease duration (%) | 33–40 | 38–45 | 43–44 | 9–23* | 100 | NR |
| Mean DMARDs failed | 0.8–0.9 | 0.8–1.0 | 1.1 | 3.0 | 0.5–0.6 | NR |
| DMARD naive (%) | 40–45 | 40–53 | 33–34 | 0 | 54–61 | 19–34 |
| Baseline HAQ-DI | 1.3 | 1.7–1.9 | 1.5 | 1.7–1.8 | 1.4–1.5 | 1.5–1.6 |
| Baseline composite x ray scores | 22.8–25.4 | 41.9–46.3 | 24.6–24.9 | 66.6–81.9 | 11.2–12.9 | 24.7–29.6 |
| Estimated yearly progression | 3.3–3.7† | 5.7–8.1† | 6.5–6.7† | 6.4–8.0† | 8.0–9.0†‡ | 6.3–7.4† |